Travere Therapeutics Inc. has announced that on May 10, 2025, its Compensation Committee granted inducement equity grants to six new employees. These grants consist of restricted stock units (RSUs) covering a total of 35,900 shares of Travere's common stock. The RSUs are issued under the terms of Travere's 2018 Equity Incentive Plan, although they were granted outside of this plan as inducements for the new employees joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting on each anniversary of the grant date, contingent upon the employees' continued service with Travere.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。